Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Abstract AKS-452, a subunit vaccine comprising an Fc fusion of the ancestral wild-type (WT) SARS-CoV-2 virus spike protein receptor binding domain (SP/RBD), was evaluated without adjuvant in a single cohort, non-randomized, open-labelled phase II study (NCT05124483) at a single site in The Netherlan...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: David G. Alleva, Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero, Melanie M. Scully, Ramya Ragupathy, Sravya Kotha, Jeffrey R. Haworth, Nishit J. Shah, Vidhya Rao, Shashikant Nagre, Shannon E. Ronca, Freedom M. Green, Stephen A. Shaw, Ari Aminetzah, Schelto Kruijff, Maarten Brom, Gooitzen M. van Dam, Todd C. Zion
स्वरूप: लेख
भाषा:English
प्रकाशित: Nature Portfolio 2024-02-01
श्रृंखला:npj Vaccines
ऑनलाइन पहुंच:https://doi.org/10.1038/s41541-024-00830-2

इंटरनेट

https://doi.org/10.1038/s41541-024-00830-2

समान संसाधन